SCHEMBL29578389

SCHEMBL29578389

COc1cc(OC)c(Cl)c(-c2cc3cnc(SC)nc3c(N3CCC(OC)CC3)n2)c1Cl

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TTK P33981 2/20 0.38
▸ FGFR4 P22455 5/20 0.34
▸ NEK2 P51955 4/20 0.33
▸ PLK1 P53350 1/20 0.33
▸ NEK1 Q96PY6 1/20 0.33
▸ PDE4B Q07343 3/20 0.33
▸ PDE3B Q13370 2/20 0.33
▸ PDE4A P27815 2/20 0.33
▸ PDE4C Q08493 2/20 0.33
▸ PDE4D Q08499 2/20 0.33
▸ PDE11A Q9HCR9 2/20 0.33
▸ TP53 P04637 1/20 0.33
▸ ATR Q13535 1/20 0.32
▸ ATRIP Q8WXE1 1/20 0.32
▸ PDE3A Q14432 1/20 0.32
▸ PDE10A Q9Y233 1/20 0.32
▸ FGFR1 P11362 2/20 0.31
▸ FGFR2 P21802 2/20 0.31
▸ FGFR3 P22607 1/20 0.31
▸ JAK2 O60674 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21240243 1.00 TTK (0.38) TTKFGFR4NEK2PLK1NEK1
SCHEMBL20331964 0.94 PDE10A (0.36) TTKFGFR4NEK2PDE3BTP53
SCHEMBL29578107 0.94 PDE10A (0.36) TTKFGFR4NEK2PDE3BTP53
SCHEMBL21240427 0.90 SUV39H2 (0.36) TTKFGFR4NEK2PLK1NEK1
SCHEMBL29578676 0.90 SUV39H2 (0.36) TTKFGFR4NEK2PLK1NEK1
SCHEMBL20331104 0.90 TTK (0.36) TTKFGFR4PDE4BPDE3BPDE4A
SCHEMBL29577692 0.90 TTK (0.36) TTKFGFR4PDE4BPDE3BPDE4A
SCHEMBL21251736 0.89 TTK (0.35) TTKNEK2PDE3BTP53PDE3A
SCHEMBL20331789 0.89 NOS1 (0.38) TTKFGFR4PDE4BPDE3BPDE4A
SCHEMBL21240537 0.89 NOS1 (0.36) FGFR4PDE4BPDE3BPDE4APDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11555036-B2 FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof ABBISKO THERAPEUTICS CO., LTD. (CN) 2023-01-17 — — US disclosed
US-20220348573-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF ABBISKO THERAPEUTICS CO., LTD. (CN) 2022-11-03 — — US disclosed
EP-3524603-B1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF ABBISKO THERAPEUTICS CO LTD (CN) 2022-06-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348573-A1 FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF FGFR4, FGFR2, FGFR1 TTK 3915/4885FGFR4 1/4885NEK2 2833/4885
US-11555036-B2 FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof FGFR4, FGFR2, FGFR1 TTK 3818/4885FGFR4 1/4885NEK2 2860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback